Pancreatic Cancer Research

ResearcherSanford ResearchActive in the last 2 years

Subhash C. Chauhan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3347-5120; OpenAlex author ID A5041474939, A5110280933; NIH RePORTER profile ID 8528912. Sources: OpenAlex.

Their work

Papers
34 (first author 0, last author 22)
Trials
0
Grants
3
Labs led
3
Collaborators
40
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers, 1 grant · 2014: 1 paper · 2015: 3 papers · 2016: none · 2017: 3 papers · 2018: 2 papers · 2019: 5 papers · 2020: 5 papers · 2021: 1 paper, 2 grants · 2022: 1 paper · 2023: 2 papers · 2024: 3 papers · 2025: 3 papers · 2026: 2 papers

Papers 34

  1. Targeted Therapy in Hepatobiliary Pancreatic Cancer (HPC): Advantages and Advancements of Antibody Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs. Co-author DOI 10.3390/ijms27062707↗
  2. MUC13-Associated Molecular Interactome in Pancreatic Cancer. Last author DOI 10.34133/csbj.0056↗
  3. Mitochondrial ribosomal protein L3 (MRPL3): An early diagnostic biomarker and potential molecular target in pancreatic cancer. Co-author DOI 10.1016/j.tranon.2025.102432↗
  4. Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research. Co-author DOI 10.3389/fphar.2025.1543112↗
  5. Correction: Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research. Co-author DOI 10.3389/fphar.2025.1662270↗
  6. CEACAM7 expression contributes to early events of pancreatic cancer. Last author DOI 10.1016/j.jare.2023.02.013↗
  7. Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.neo.2023.100951↗
  8. Honey Targets Ribosome Biogenesis Components to Suppress the Growth of Human Pancreatic Cancer Cells. Co-author DOI 10.3390/cancers16193431↗
  9. Integrative big transcriptomics data analysis implicates crucial role of MUC13 in pancreatic cancer. Last author DOI 10.1016/j.csbj.2023.04.029↗
  10. An integrated computational biology approach defines the crucial role of TRIP13 in pancreatic cancer. Last author DOI 10.1016/j.csbj.2023.11.029↗
  11. Reprogramming of pancreatic adenocarcinoma immunosurveillance by a microbial probiotic siderophore. Last author DOI 10.1038/s42003-022-04102-4↗
  12. Steviol Represses Glucose Metabolism and Translation Initiation in Pancreatic Cancer Cells. Co-author DOI 10.3390/biomedicines9121814↗
  13. Biophysical changes caused by altered MUC13 expression in pancreatic cancer cells. Last author DOI 10.1016/j.micron.2019.102822↗
  14. Novel Paclitaxel Nanoformulation Impairs De Novo Lipid Synthesis in Pancreatic Cancer Cells and Enhances Gemcitabine Efficacy. Last author DOI 10.1021/acsomega.0c00793↗
  15. Pluronic Polymer-Based Ormeloxifene Nanoformulations Induce Superior Anticancer Effects in Pancreatic Cancer Cells. Last author DOI 10.1021/acsomega.9b03382↗
  16. Protein kinase D1 regulates metabolic switch in pancreatic cancer via modulation of mTORC1. Co-author DOI 10.1038/s41416-019-0629-9↗
  17. APE1 Promotes Pancreatic Cancer Proliferation through GFRα1/Src/ERK Axis-Cascade Signaling in Response to GDNF. Co-author DOI 10.3390/ijms21103586↗
  18. Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer. Last author DOI 10.1016/j.biomaterials.2019.04.005↗
  19. Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. Last author DOI 10.1016/j.nano.2019.102027↗
  20. Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer. Last author DOI 10.1186/s13046-018-1009-7↗
  21. Novel Mechanistic Insight into the Anticancer Activity of Cucurbitacin D against Pancreatic Cancer (Cuc D Attenuates Pancreatic Cancer). Last author DOI 10.3390/cells9010103↗
  22. Gemcitabine Combination Nano Therapies for Pancreatic Cancer. Last author DOI 10.3390/pharmaceutics11110574↗
  23. Clinical significance of MUC13 in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.hpb.2017.12.003↗
  24. MUC13 contributes to rewiring of glucose metabolism in pancreatic cancer. Co-author DOI 10.1038/s41389-018-0031-0↗
  25. Restitution of Tumor Suppressor MicroRNA-145 Using Magnetic Nanoformulation for Pancreatic Cancer Therapy. Last author DOI 10.1007/s11605-016-3222-z↗
  26. MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression. Co-author DOI 10.1038/onc.2016.218↗
  27. miR-145: Revival of a Dragon in Pancreatic Cancer. Last author PMID 28616589↗
  28. Nanoparticle formulation of ormeloxifene for pancreatic cancer. Last author DOI 10.1016/j.biomaterials.2015.02.082↗
  29. Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer. Last author DOI 10.1158/0008-5472.can-14-2397↗
  30. Revisiting stroma in pancreatic cancer. Last author DOI 10.18632/oncoscience.198↗
  31. MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer. Last author DOI 10.18632/oncotarget.2281↗
  32. Targeting microRNAs in pancreatic cancer: microplayers in the big game. Last author DOI 10.1158/0008-5472.can-13-1288↗
  33. Novel curcumin-loaded magnetic nanoparticles for pancreatic cancer treatment. Last author DOI 10.1158/1535-7163.mct-12-1227↗
  34. Vitamin E succinate inhibits survivin and induces apoptosis in pancreatic cancer cells. Co-author DOI 10.1007/s12263-011-0242-x↗

Grants 3

  1. Development of Targeted Nanotechnology Platform for Pancreatic Cancer R01CA206069↗
  2. Targeted Nanotherapy for Pancreatic Cancer R01CA210192↗
  3. Aspects of MUC13 Mucin in Cancer R01CA142736↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Murali Mohan Yallapu · 27 shared papers, 2013–2026 · strength 3.43
  2. Sheema Khan · 23 shared papers, 2013–2025 · strength 2.46
  3. Meena Jaggi · 23 shared papers, 2013–2024 · strength 2.16
  4. Anupam Dhasmana · 7 shared papers, 2023–2026 · strength 1.65
  5. Swati Dhasmana · 6 shared papers, 2023–2026 · strength 1.38
  6. Bilal Bin Hafeez · 9 shared papers, 2017–2025 · strength 1.15
  7. Stephen W. Behrman · 11 shared papers, 2014–2025 · strength 1.12
  8. Sonam Kumari · 10 shared papers, 2017–2022 · strength 0.98
  9. Shafiul Haque · 4 shared papers, 2023–2026 · strength 0.90
  10. Saini Setua · 8 shared papers, 2017–2020 · strength 0.71
  11. Mohammed Sikander · 7 shared papers, 2014–2022 · strength 0.60
  12. Neeraj Chauhan · 8 shared papers, 2013–2020 · strength 0.55
  13. Shabia Shabir · 2 shared papers, 2025 · strength 0.47
  14. Russell Moreland · 2 shared papers, 2025 · strength 0.47
  15. Mudassier Ahmad · 2 shared papers, 2024–2025 · strength 0.46
  16. Tushar Deb Nath · 1 shared paper, 2026 · strength 0.43
  17. Debasish Bandyopadhyay · 1 shared paper, 2026 · strength 0.43
  18. Vivek Kumar Kashyap · 4 shared papers, 2018–2022 · strength 0.38
  19. Upender Manne · 2 shared papers, 2023–2024 · strength 0.38
  20. Farrukh Afaq · 2 shared papers, 2023–2024 · strength 0.38
  21. Andrew E. Massey · 3 shared papers, 2019–2020 · strength 0.33
  22. Advait B. Shetty · 2 shared papers, 2019–2020 · strength 0.21
  23. Sooryanarayana Varambally · 1 shared paper, 2024 · strength 0.20
  24. Moh'd M. Khushman · 1 shared paper, 2024 · strength 0.20
  25. Sumit Agarwal · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.